🇺🇸 Pf-07284892 in United States

9 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Abdominal Pain — 1 report (11.11%)
  2. Blood Bilirubin Increased — 1 report (11.11%)
  3. Colitis — 1 report (11.11%)
  4. Dyspnoea — 1 report (11.11%)
  5. Nausea — 1 report (11.11%)
  6. Peripheral Sensory Neuropathy — 1 report (11.11%)
  7. Pulmonary Embolism — 1 report (11.11%)
  8. Pyrexia — 1 report (11.11%)
  9. Vomiting — 1 report (11.11%)

Source database →

Pricing & reimbursement

Pf-07284892 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Pf-07284892 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Pf-07284892 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Pf-07284892 cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.